FOXP3 and neoplasm: FoxP3+ Tregs in the tumor impede effective anti-cancer immune responses and diminish the effect of PD-1/PD-L1 monoclonal antibodies; in contrast, Th17 cells in this context act as promoters of tumor growth (74).